Search results for "Biological product"

showing 6 items of 126 documents

An update on medical management on Crohn's disease.

2014

The management of Crohn's disease (CD) is continuously evolving. New issues emerging from more recent studies could influence the decision-making process in clinical practice.The aim of this review article is to highlight critical issues on the management of CD, new evidence from clinical trials, long-term prospective studies and real life experience, beyond the current guidelines.The role of mucosal healing in clinical practice is uncertain, clinical remission remains the primary end point. The timing for the definition of steroid-resistant CD should be considered between 2 and 4 weeks. Early treatment strategy with immunomodulators is effective for inducing remission but no controlled dat…

medicine.medical_specialtyCombination therapyAzathioprineDiseasechemistry.chemical_compoundMesalazineAdjuvants ImmunologicCrohn DiseaseClinical endpointMedicineHumansPharmacology (medical)Prospective StudiesIntensive care medicinePharmacologyCrohn's diseaseBiological ProductsClinical Trials as Topicbusiness.industryTumor Necrosis Factor-alphaRemission InductionGeneral Medicinemedicine.diseaseReview articleSurgeryClinical trialchemistryPractice Guidelines as TopicDrug Therapy CombinationbusinessImmunosuppressive Agentsmedicine.drugExpert opinion on pharmacotherapy
researchProduct

Review of biologics in allergic contact dermatitis

2020

The resistant and recalcitrant nature of severe allergic contact dermatitis (ACD) makes its management challenging. With advances in the understanding of the cellular and molecular pathogenesis of ACD, newer therapeutic targets are becoming apparent. In particular, the use of biologics has gained momentum, given the specificity of their action. This article aims to review the presently available data on the use of biologics in ACD. English-language-based literature available on the use of biological therapy was thoroughly probed in the following databases as on October 14, 2019: PubMed, Google Scholar, The Cochrane library, Embase, Scopus, and EBSCO. The following keywords were used: "conta…

medicine.medical_specialtyDermatologyOmalizumabEtanercept030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineUstekinumabmedicineAdalimumabHumansImmunology and Allergy030212 general & internal medicineAllergic contact dermatitisBiological Productsbusiness.industryPatch Testsmedicine.diseaseDermatologyDupilumabInfliximabTreatment OutcomeDermatitis Allergic ContactSecukinumabbusinessmedicine.drugContact Dermatitis
researchProduct

Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease

2014

Many placebo controlled trials and meta-analyses evaluated the efficacy of different drugs for the treatment of inflammatory bowel disease (IBD), including immunosuppressants and biologics. Their use is indicated in moderate to severe disease in non responders to corticosteroids and in steroid-dependent patients, as induction and maintainance treatment. Infliximab, as well as cyclosporine, is considered a second line therapy in the case of severe ulcerative colitis, or non-responders to intravenous corticosteroids. An adequate dosage and duration of therapy with thiopurines should be reached before evaluating their efficacy. Methotrexate is a valid option in patients with Crohn’s disease bu…

medicine.medical_specialtySettore MED/09 - Medicina InternaCombination therapyInflammatory bowel diseaseGastroenterologyimmunosuppresantbiologicsinflammatory bowel diseaseCrohn DiseaseGastrointestinal AgentsRisk FactorsInternal medicinemedicineimmunomodulators.optimization. treatmentHumansTopic HighlightBiological ProductsGastrointestinal agentCrohn's diseaseThiopurine methyltransferasebiologybusiness.industryGastroenterologyGeneral Medicinemedicine.diseaseUlcerative colitisTacrolimusInfliximabSurgeryTreatment Outcomebiology.proteinColitis UlcerativeDrug Therapy CombinationbusinessImmunosuppressive Agentsmedicine.drug
researchProduct

Are biological drugs effective and safe in older severe asthmatics?

2019

Introduction: The treatment of asthma in older ages follows the recommendations of international guidelines for the management of asthma in younger ages, although older age has always represented an exclusion criterion for eligibility to pharmacological trials. This poses a clinical challenge when deciding whether elderly severe asthmatics are candidates for biological drugs. Areas covered: The current article has a narrative structure to review the current literature on efficacy and safety of novel pharmacological drugs against immunoglobulins and interleukins that mediate and orchestrate the main inflammatory pathways in severe asthma, in order to explore whether older subjects (i.e. >…

medicine.medical_specialtypulmonary eosinophilia/drug therapyeducationImmunoglobulinsmonoclonal030204 cardiovascular system & hematologySettore MED/10 - Malattie Dell'Apparato RespiratorioAnti-asthmatic AgentSeverity of Illness IndexBiological drugs03 medical and health sciences0302 clinical medicineimmune system diseasesInternal medicineSeverity of illnessImmunoglobulinHumansMedicineAnti-Asthmatic AgentPharmacology (medical)Age FactorAnti-Asthmatic AgentsAsthmaAgedRandomized Controlled Trials as TopicBiological ProductsAsthma/drug therapybiologyhumanizedbusiness.industryInterleukinsAge FactorsGeneral MedicineInterleukinmedicine.diseaseAsthmarespiratory tract diseasesantibodie030220 oncology & carcinogenesisMonoclonalPractice Guidelines as Topicbiology.proteinBiological Productanti-asthmatic agents/pharmacologyAntibodybusinessHuman
researchProduct

Comparison of different theory models and basis sets in the calculation of 13C NMR chemical shifts of natural products.

2004

The influence of the calculation method in mimicking experimental 13C NMR chemical shifts of 15 low-polarity natural products singularly containing 10–20 carbon atoms was investigated by employing different quantum chemistry approaches and basis sets, both in the preliminary geometry optimizations and in the following single-point 13C GIAO calculations of the NMR chemical shifts. The geometries of the involved species were optimized at the PM3, HF, B3LYP and mPW1PW91 levels whereas the 13C NMR parameters were determined at the HF, B3LYP and mPW1PW91 levels. Different combinations of basis sets were also tested. The consistency and efficiency of the considered combinations of geometry optimi…

natural productBiological ProductsMagnetic Resonance SpectroscopyBasis (linear algebra)Databases FactualChemistryChemical shiftstructure elucidationStatistical parameterGeneral ChemistryGIAOCarbon-13 NMRQuantum chemistryNMRModels ChemicalComputational chemistryAb initio quantum chemistry methodsab initiocalculationData Interpretation Statistical13CNMRQuantum TheoryGeneral Materials ScienceDensity functional theorydensity functional theorySoftwareMagnetic resonance in chemistry : MRC
researchProduct

A Systematic review to identify the effects of biologics in the feet of patients with rheumatoid arthritis

2020

Background and objective: Ninety percent of patients with rheumatoid arthritis (RA) feel foot pain during the disease process. Pharmacological treatment of RA has a systematic effect on the body and includes: Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs) and biologics. The objective of our review was to examine the impact of biologics on patients with RA ‘foot. Methods and material: A systematic review of randomized control trials and observational studies that evaluated the efficacy of biologics against other pharmacological treatment, and included a foot outcome measure. The search covered MEDLINE Ovid, Pubmed, CINAHL, Cochrane Library, Evidence Sear…

rheumatoid arthritismedicine.medical_specialtyMEDLINEReviewCINAHLCochrane LibraryDMARDslaw.inventionArthritis Rheumatoid03 medical and health sciences0302 clinical medicinesystematic reviewRandomized controlled triallawInternal medicineHumansMedicinebiologics030212 general & internal medicineRisk factor030203 arthritis & rheumatologylcsh:R5-920Biological ProductsArtritisbusiness.industryGeneral Medicinemedicine.diseaseNewcastle–Ottawa scaleAntirheumatic AgentsRheumatoid arthritisfeetObservational studylcsh:Medicine (General)business
researchProduct